BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » cell therapy » Page 17

Sernova Secures Exclusive Worldwide Rights to Stem Cell Technologies Related to Diabetes

September 10, 2015 By Cade Hildreth (CEO) Leave a Comment

Sernova Secures Exclusive Worldwide Rights to Stem Cell Technologies for Diabetes

Sernova Diabetes TreatmentIn a major announcement released today, Sernova Corporation stated that it had secured exclusive worldwide rights to patent-pending technologies developed by two leading researchers at the University Health Network (UHN) of Toronto, Canada. The license pertains to the “development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.”

The market for treatment of diabetes is massive, as the Center for Disease Control (CDC) estimates that are 29 million people living with diabetes in the United States, which represents approximately 9.3% of the U.S. population.

Worldwide, 370 million people are afflicted by the disease.

If successful, a cell therapy approach to the treatment of diabetes would be revolutionary. To learn more about the announcement, see the full press release from Sernova below, printed with permission from Janet Vasquez, press contact for Sernova. [Read more…]

Filed Under: Stem Cells Tagged With: cell therapy, diabetes, Sernova

My Story: President of a Stem Cell Market Research Firm and a Stem Cell Patient

March 12, 2015 By Cade Hildreth (CEO) 1 Comment

Cade Hildreth, Autologous Stem Cell Patient

For the past 15 years, I have studied stem cells, including technology and research advances, as well as market trends. I have been fascinated with them for most of my adult life, founding BioInformant as the first and only market research firm to specialize in the stem cell industry.

As a result of this decision, I have had the honor of serving thousands clients from across the stem cell industry and been interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine.

However, it was only recently that I experienced the power of stem cells to impact my own life and health.

[Read more…]

Filed Under: MSCs, Stem Cells Tagged With: autologous, cell therapy, regenerative medicine, stem cells

Induced Pluripotent Stem Cell News Round-Up| February 15-22, 2015

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

iPSC News Round-Up February 2014

The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: cell therapy, current events, iPSC, market update, stem cells

Induced Pluripotent Stem Cell (iSPC) News Round-Up| January 2015

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

iPSC News Round-Up February 2014

The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: cell therapy, current events, iPSC

  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.